Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pumping chemo straight into the liver: a new way to fight pancreatic cancer spread?

NCT ID NCT07845617

Disease control Sponsor: AdventHealth Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 29, 2026 · Last updated Sep 30, 2026 · Updated 1 time

Summary

This study looks at whether delivering chemotherapy directly into the liver through a small implanted pump can help people with pancreatic or duodenal adenocarcinoma that has spread to the liver after surgery and standard chemotherapy. Participants receive floxuridine through the pump and researchers track tumor response on scans, progression-free survival, overall survival, and complications from the pump or procedure. The study is small, with about 10 participants, and aims to see if this approach is feasible and worth testing further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
floxuridine (FUDR) chemotherapy delivered through a hepatic artery infusion pump
What this could lead to
If it works, this approach could offer a way to control cancer that has spread to the liver in people whose pancreatic or duodenal cancer was already treated with surgery and chemotherapy.
What could go wrong
The study is very small, with only 10 participants, and it is a feasibility study, so it mainly checks whether the approach can be done and monitored, not whether it clearly extends life. Pump placement and liver-directed chemotherapy carry risks of surgical complications, catheter problems, and liver toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

AdventHealth Orlando

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years * Histologically confirmed pancreatic or duodenal adenocarcinoma * Completed or currently receiving curative-intent treatment * Evidence of isolated or liver-dominant metastases (radiographic or clinical) * Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team * Scheduled for HAIP placement at AdventHealth Orlando Exclusion Criteria: \- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ampullary adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ampulla of vater adenocarcinoma carcinoma of duodenum duodenal adenocarcinoma duodenum cancer malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ampullary adenocarcinoma Duodenal adenocarcinoma Duodenal cancer Pancreas adenocarcinoma Pancreas cancer with hepatic metastase

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AdventHealth Orlando

    RECRUITING

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.